Charity Annual Report and Accounts 2021-22

Why we need continuous support – our future plans 2022/23

We will continue to raise funds for the Academy of Surgical Oncology which is outlined earlier in this report. With an Academy of Surgical Oncology, we will be able to carry out surgical trials - something that very few cancer centres in the UK do. We want to carry out a ground-breaking combination of surgical and clinical treatment together, meaning we can lead the way in this unique type of surgical clinical trial on a national and global scale. The potential this holds for the future of cancer treatment and our patients is huge. The Academy will be located in the new research building. We will also continue to raise funds for our ‘Bloods Closer to Home’ service which is also outlined earlier in this report. This outreach programme is a simple change which will make a huge difference to patients’ wellbeing, supporting both their mental and physical health. We now plan to open 20 new clinics to reach the people most in need, hopefully reaching 1,000 people per week through the local service. In the long-term, we hope this service can be offered to all patients, including those on clinical trials. The hepato-pancreatico-biliary (HPB) and neuroendocrine tumour (NET) team here at The Christie, led by Professor Juan Valle, focuses on treating patients with cancer of the pancreas, liver, bile ducts (cholangiocarcinoma and gallbladder) and tumours of the neuroendocrine system. We will be looking to fund a clinical research fellow for two years. This fellow will help to improve patient outcomes through involvement in potentially practice changing research and also through exposure of The Christie as a leading destination for clinical research fellowship training and development. The additional support provided by these fellowship posts enables the HPB/NET clinicians to dedicate more of their time to research and educational activities. Previous funding has developed two highly successful fellows and we wish to continue this success to avoid gaps in research and clinical activities within the HPB/NET disease group.

as 15,978 ePROMS (digital patient reported outcome measures) have been completed and 5,458 patients have been enrolled onto the service to date. Completion rates have ranged from 50% to 99% across the ten services that are live, with very positive feedback from patients. It has gained significant interest from other NHS organisations keen to learn from our experience. These are just a few examples of areas we will be funding. More details and more projects can be found on our website The Christie charity.

The only way of being able to offer better treatment options to patients is by running well-designed, cutting-edge clinical trials. Our clinical research fellows review new patients, discuss and recommend clinical trial options where appropriate, recruit patients into clinical trials and are involved in, and oversee, the day-to-day activities of clinical trial delivery including patient assessment, addressing research nurse and trial co-ordinator queries and attending to adverse event management for these patients. We will continue to fund our pioneering online service to help improve patient experience, survival and quality of life. ‘My Christie-My Health’ enables patients to complete health questionnaires online throughout their treatment, helping them to monitor symptoms at home, as well as providing healthcare professionals with vital insight into the patient’s physical and mental health, short and long-term symptoms, and impact on quality of life. So far significant progress has been made

20